Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting.

Autor:	Papaioannu Borjesson R; Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Clemente T; Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Diotallevi S; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Lolatto R; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Forniti A; Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Bottanelli M; Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy., Galli L; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Gianotti N; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Muccini C; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Hasson H; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Castagna A; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Spagnuolo V; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Nov 21. Date of Electronic Publication: 2024 Nov 21.
DOI:	10.1093/jac/dkae420
Abstrakt:	Background: Virological failures of first-line second-generation (SG) INSTI-based regimens are rare, usually characterized by low viremia and absence of drug resistance mutations. Objectives: To explore the efficacy of rescue regimens introduced after virological failure (VF) to a first-line SG-INSTI therapy. Patients and Methods: This was a retrospective study on people living with HIV (PWH) failing a first-line SG-INSTI regimen [DTG/3TC, BIC/FTC/TAF, DTG-based three-drug regimen (DTG-3DR)] between 24 March 2016 and 31 December 2021. Follow-up accrued from the second viral load (VL) ≥ 50 copies/mL under SG-INSTI regimen (baseline) until virological success (VS, achievement of at least one VL < 50 copies/mL after baseline) or last visit. Cumulative probabilities of VS were estimated by Kaplan-Meier curves and compared using a log-rank test. Results: Overall, of 521 naïve PWH who started a first-line SG-INSTI regimen, 45 (8.6%) had VF after a median of 14.9 (IQR = 6.9-25.9) months: 33/395 (8.4%) individuals failed a DTG-3DR, 11/102 (10.8%) a BIC/FTC/TAF and 1/24 (4.2%) failed a DTG/3TC.At baseline, 12/45 (27%) PWH changed antiretroviral therapy [median baseline VL 134 (IQR = 81-233) copies/mL], while 33 (73%) maintained their failing regimen [median baseline VL 75 (IQR = 60-145) copies/mL].During a median follow-up of 5.13 (IQR = 3.8-7.1) months, 34 (75.6%) PWH achieved VS: 25/33 (75.8%) maintaining their failing regimen, 9/12 (75%) switched regimen; the estimated 6- and 12-months probabilities of VS were 59% and 84%, respectively.There was no difference in VS curves between PWH who maintained their failing regimen and those who switched therapy. Conclusions: Most individuals remained on their failing regimen, achieving spontaneous virological suppression in most cases. These data help to understand a real-life VF scenario in the context of the current SG-INSTI era. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu